They found that regular use of NSAIDs in the past 5 or more years was associated with a reduced risk of prostate cancer, but current NSAID use was not associated with decreased prostate cancer risk.[17] The measurement of NSAID use in our study was based on self-report reflecting whether respondents reported current use of nonaspirin NSAIDs or COX-2 inhibitors. The gene discussed is PTGS2; the disease is prostate carcinoma.